What is Selank?
Selank is a research peptide discussed for anxiety-related effects. Its small clinical literature needs careful attention to study design and replication.
Video overview · 2:47
Semax vs Selank: Do These Russian "Brain Peptides" Actually Work? (The Evidence)
What each peptide is, the rat brain studies behind the memory claim, the small Russian stroke and anxiety studies, why no placebo-controlled trial has tested memory or focus in healthy people, and their FDA and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
Semax and Selank are two short peptides developed in Russia and sold online as brain boosters: Semax for focus, Selank for calm. Neither is FDA approved, and the evidence behind them is thinner than the marketing suggests. Here is what is actually known.
Semax is seven amino acids long, built from a fragment of the stress hormone ACTH that researchers once linked to learning. Selank was developed in Russia and studied mainly for anxiety. Both are reported to be used as medicines in Russia, but little of their research reached international journals, and online they are sold as powders and nasal sprays outside any quality control.
Most of the memory story comes from rats. A single nasal application of Semax raised BDNF, a protein that supports brain-cell growth, by up to one point four times in the rat brain's memory center, and treated rats learned an avoidance task better. Whether any of that means sharper focus in healthy people has not been shown.
The human studies are small, mostly Russian, and not clearly blinded. Semax was added to standard care in thirty stroke patients, compared with eighty others, and the authors reported faster recovery. Selank was compared with two anxiety drugs, in sixty and sixty-two patients, and reported similar anxiety improvement. None had a placebo group.
What about healthy people? For Semax, we found no published placebo-controlled trial that measured memory or focus. Two Russian studies in healthy volunteers looked only at brain scans. And when the hormone fragment Semax was built from was properly tested in sixty healthy people, it did not improve working memory.
Neither is FDA approved. The FDA says it lacks important safety information for both and flags possible immune reactions from impurities, and in 2026, FDA staff advised against allowing Semax in pharmacy compounding. Because they are reported to be registered in Russia, their status under anti-doping rules is unclear.
Does Semax boost memory in healthy people? Unproven: no placebo-controlled trial has measured it. Does Selank treat anxiety? The evidence is limited to two small studies without a placebo group. And is the Semax and Selank combination tested? No study has tested them together.
The bottom line: Semax and Selank rest on rat studies and small Russian reports. The memory claim for Semax is unproven in healthy people, Selank's anxiety evidence lacks a placebo group, and neither is FDA approved. For the full comparison and every source, see PepsRadar dot com.
Biological role or research focus
Anxiety-related peptide research.
A small comparative study is not a complete evidence base for routine anxiety treatment.
Role reference: [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. ↗
Names you may encounter
selank acetate · TP-7
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Experimental anxiety-related peptide
- Main research area
- Anxiety and neurobiology research
- Evidence featured
- Small human comparative study
- Source check
- October 4, 2026
Quick answers
- Is Selank FDA approved?
- No. No FDA-approved drug contains Selank. Source ↗
- Is Selank safe?
- Not FDA-approved. Small Russian comparison studies report tolerability, but FDA says it lacks important safety information, so its risks are uncertain. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Selank banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
- Has the FDA taken action over Selank?
- Yes. Our records list 2 FDA actions naming it, most recently on November 10, 2021: FDA warning letter to a clinic-based compounder (Guyer Institute) stating Selank had not been nominated for the 503A bulks list and could not be used under the 503A exemptions. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Anxiety-disorder comparison (2014) | Small human comparative study | 60 patients with phobic-anxiety or somatoform disorders. |
| Selank versus medazepam · 2008 (2008) | Human active-comparator study | 62 patients with generalized anxiety disorder or neurasthenia: 30 received Selank and 32 medazepam. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Small human comparative study · 2014
Anxiety-disorder comparison
[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].
- Population / model
- 60 patients with phobic-anxiety or somatoform disorders.
- Study design
- Selank compared with phenazepam; abstract-level report.
- Main finding
- The authors reported anxiety improvement, tolerability, and quality-of-life findings, including effects persisting a week after treatment.
- Limits & context
- The abstract does not adequately resolve allocation, blinding, effect size, or long-term harms. It is not a placebo-controlled replication or proof of routine effectiveness across anxiety disorders.
Human active-comparator study · 2008
Selank versus medazepam · 2008
What does the earlier anxiety report add?
- Population / model
- 62 patients with generalized anxiety disorder or neurasthenia: 30 received Selank and 32 medazepam.
- Study design
- Psychometric assessments and blood enkephalin measurements; PubMed indexes a randomized trial, but the English abstract does not describe allocation concealment or blinding.
- Main finding
- The authors reported similar anxiety effects between groups, with additional anti-asthenic and psychostimulant findings for Selank.
- How to read it
- Similar observed effects are not a formal demonstration of equivalence or noninferiority.
- Limits & context
- No placebo group or numerical effect estimates are described in the abstract. The Russian-language full article needs qualified review. This does not establish effectiveness for every anxiety disorder or safety with other psychiatric medicines.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming Selank as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Search additional PubMed records ↗Risks & interactions
Not FDA-approved. Small Russian comparison studies report tolerability, but FDA says it lacks important safety information, so its risks are uncertain.
Two small Russian comparison studies (60 and 62 patients) without placebo groups reported anxiety outcomes and tolerability. Their abstracts do not detail adverse events. Interactions with other psychiatric medicines and repeated-use risks are unstudied.
Unassessed: little human safety data
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- Possible immune reactions (immunogenicity) and peptide impurities, per FDA's compounding safety listing
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks ↗ · Selank vs phenazepam in anxiety disorders (2014) ↗ · Selank in generalized anxiety and neurasthenia (2008) ↗
Safety evidence & remaining uncertainty
FDA identifies inadequate safety information. A favorable short report cannot rule out interactions, uncommon reactions, or risks of repeated use.
Source: FDA · Peptide compounding safety concerns ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "Selank acetate (TP-7)". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named. S0 only applies to substances with no government approval anywhere; Selank is reported to be registered as a medicine in Russia (not verified here), so whether S0 applies is uncertain. Athletes should check with their anti-doping organization. source
FDA actions
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing Selank among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
- FDA warning letter to a clinic-based compounder (Guyer Institute) stating Selank had not been nominated for the 503A bulks list and could not be used under the 503A exemptions. (2021-11-10) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
A small comparison with phenazepam is summarized below. Its abstract leaves important design questions unresolved, and it does not establish a broad routine anxiety-treatment role.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
The selected human report investigates symptom changes rather than establishing a complete molecular mechanism. Proposed neurobiological explanations should not be mistaken for demonstrated clinical effectiveness.
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- A small comparative study is not a complete evidence base for routine anxiety treatment.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Is the study clearly a blinded placebo-controlled trial?
The available abstract does not establish that. It reports comparison with phenazepam.
Does a small favorable study settle an anxiety-treatment question?
No. Replication, effect size, allocation methods, and longer-term outcomes remain important.
References & editorial record
- FDA · Compounding safety concerns ↗
- PubMed · Small human comparative study · PMID 25176261 ↗
- Selank versus medazepam · 2008 · 2008 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
